KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Zimmer Biomet Holdings (ZBH) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Zimmer Biomet Holdings' Cash & Equivalents rose 12718.8% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 12718.8%. This contributed to the annual value of $525.5 million for FY2024, which is 2638.29% up from last year.
  • Per Zimmer Biomet Holdings' latest filing, its Cash & Equivalents stood at $1.3 billion for Q3 2025, which was up 12718.8% from $556.9 million recorded in Q2 2025.
  • In the past 5 years, Zimmer Biomet Holdings' Cash & Equivalents ranged from a high of $1.4 billion in Q1 2025 and a low of $292.1 million during Q3 2023
  • Over the past 5 years, Zimmer Biomet Holdings' median Cash & Equivalents value was $435.8 million (recorded in 2022), while the average stood at $595.1 million.
  • Per our database at Business Quant, Zimmer Biomet Holdings' Cash & Equivalents tumbled by 7023.75% in 2021 and then soared by 25229.01% in 2025.
  • Quarter analysis of 5 years shows Zimmer Biomet Holdings' Cash & Equivalents stood at $378.1 million in 2021, then fell by 0.63% to $375.7 million in 2022, then grew by 10.67% to $415.8 million in 2023, then grew by 26.38% to $525.5 million in 2024, then soared by 145.99% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $556.9 million in Q2 2025 and $1.4 billion in Q1 2025.